Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds
Chemotherapy linked to immune system changes in ovarian cancer patients
An observational cohort study of 107 HGSOC patients and 50 healthy controls found chemotherapy was associated with modulation of NK cell rec…
Chemotherapy in ovarian cancer may restore natural killer cell markers to healthy levels and boost proteins that help immune cells fight tum…
Research across Cancer
Related studies from across the Cancer family.
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Case report details multimodal treatment for aggressive thyroid carcinoma
First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule
A rare ovarian tumor diagnosis explained in a single patient case
This source is a case report review describing a 27-year-old female patient with an ovarian borderline mucinous tumor and carcinosarcomatous…
Doctors treated a 27-year-old woman with a rare ovarian tumor using fertility-sparing surgery and chemotherapy, with no signs of the cancer …
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review
Why tumors grow back inside the radiation beam, not just at the edges
This retrospective single-center review of 41 patients with high-grade glioma found that central recurrence was the most common pattern (36.…
New data shows brain tumors often return in the middle of the radiation zone, suggesting biology, not just targeting errors, drives failure.
Nomogram predicts survival in uterine serous carcinoma using SEER and hospital data
New Tool Helps Doctors Predict Uterine Cancer Survival
This retrospective cohort study of 8,204 patients with uterine serous carcinoma developed a nomogram for overall survival prediction.
A new computer model helps doctors give honest survival estimates for patients with a deadly form of uterine cancer.
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center
Lockdowns Didn't Hurt Ovarian Cancer Survival
This retrospective cohort study of 218 patients at Bern University Hospital found primary ovarian cancer diagnoses decreased in 2020 and 202…
When the world shut down in 2020, hospitals faced a scary reality.
Conference report on AI ensemble for histopathological classification of ovarian carcinoma subtypes
AI Can Now Tell Apart Two Ovarian Cancers That Look Nearly Identical
This conference report describes a preclinical computational study using an attention-guided CNN ensemble to classify high-grade versus low-…
This technology could prevent misdiagnosis and ensure patients get the most effective treatment for their specific cancer type from day one.
Separate molecular profiling of mixed endometrial carcinoma components yields limited prognostic data in a small retrospective cohort
Separate tumor profiling may reveal hidden risks in mixed endometrial cancer
This hypothesis-generating retrospective cohort analysis included 8 patients with mixed endometrial carcinomas (MEEC).
In mixed endometrial cancer, testing each tumor component separately could uncover risk profiles that standard testing misses.
GSC-associated gene signature predicts survival in adult and pediatric high-grade glioma patients
New Brain Tumor Test Predicts Survival More Accurately
This cohort study evaluated a GSC-associated gene signature involving the FAM86B1/FAM86B2 axis in adult and pediatric high-grade glioma pati…
A new model uses specific genes to predict how long patients might live with aggressive brain tumors.
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.